Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trial of Verapamil in Chronic Rhinosinusitis
NCT02454608 · Benjamin Bleier · NA · terminated · last registry update 2018-06-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Evidence that the dose is insufficient.” | – | Registry record, Benjamin Bleier |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CACNA1C within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-04-05Phase 3 first posted: doaa rashwan, Dronedarone + Amiodarone (NCT03905759)
- 2019-01-30Results posted on the registry: University of Alabama at Birmingham, Verapamil + Placebo (NCT02372253)
- 2019-01-23Phase 3 first posted: EMS, LENINGRADO association + Indapamide SR 1.5 MG (NCT03814109)
- 2018-11-20Also stopped (withdrawn): University of South Florida, Diltiazem Hydrochloride + Sugar Pill (NCT01645826)
- 2018-08-09Phase 3 first posted: Hermina Heart Center Kemayoran, Nitroglycerin (NCT03622060)
- 2018-06-26Phase 3 first posted: Samsung Medical Center, Edoxaban + Enoxaparin (NCT03570281)
- 2018-04-11Also stopped (terminated): Center Laboratories, Inc., R-verapamil 75 mg tablet + Placebo (NCT02209155)
- 2018-02-23Results posted on the registry: AstraZeneca, AZD7986 + Verapamil (NCT02653872)
- 2017-11-14Phase 3 first posted: Keimyung University Dongsan Medical Center, Phloroglucin(Flospan®) + Normal saline (NCT03342118)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision